P16INK4a overexpression is associated with poor clinical outcome in ovarian carcinoma.
Raspollini
M R
MR
Amunni
G
G
Villanucci
A
A
Baroni
G
G
Taddei
G L
GL
D018262:Adenocarcinoma, Clear Cell / Q000737:chemistry* / Q000401:mortality* / Q000628:therapy; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis*; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000737:chemistry / Q000401:mortality; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000401:mortality* / Q000628:therapy; D010052:Ovariectomy / Q000379:methods; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D015996:Survival Rate
D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16